# EDGAR Filing Document

**Accession Number:** 0001479681
**File Stem:** 0001628280-26-016007
**Filing Date:** 2026-3
**Character Count:** 24423
**Document Hash:** fffc4d7d2d2bd9bd0f98790fb6c98b05
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-016007.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0001628280-26-016007

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20260309

**DATE AS OF CHANGE**: 20260310

**EFFECTIVENESS DATE**: 20260309

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nutex Health Inc.
- **CENTRAL INDEX KEY:** 0001479681
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-BUSINESS SERVICES, NEC [7389]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 113363609
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294176
- **FILM NUMBER:** 26737902

**BUSINESS ADDRESS:**
- **STREET 1:** 1776 YORKTOWN ST
- **STREET 2:** SUITE 700
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77056
- **BUSINESS PHONE:** (713) 660-0557

**MAIL ADDRESS:**
- **STREET 1:** 1776 YORKTOWN ST
- **STREET 2:** SUITE 700
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77056

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nutex Health, Inc.
- **DATE OF NAME CHANGE:** 20220404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Clinigence Holdings, Inc.
- **DATE OF NAME CHANGE:** 20191113

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** iGambit, Inc.
- **DATE OF NAME CHANGE:** 20091230

**As filed with the Securities and Exchange Commission on March 9, 2026**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Registration No. 333-**<br>

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION<br>Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**NUTEX HEALTH INC.**<br> (Exact Name of Registrant as Specified in its Charter)

---

| | |
|:---|:---|
| **Delaware**<br>(State or other jurisdiction of incorporation or organization) | **11-3363609**<br>(I.R.S. Employer Identification No.) |

---

**1776 Yorktown Street, Suite 700<br>Houston, TX 77056**<br> (Address of principal executive offices) (Zip code)

**Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan**<br> (Full title of the plan)

**Elisa V. Luqman<br>Chief Legal Officer – SEC<br>1776 Yorktown Street, Suite 700<br>Houston, TX 77056**<br> (Name and address of agent for service)

**(713) 660-0557**<br> (Telephone number, including area code, of agent for service)

***Copies to:***<br>

**Gislar Donnenberg**

**Troutman Pepper Locke LLP**

**600 Travis St., Suite 2800**

**Houston, Texas 77002**

**(713) 226-1200**<br>

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| **Large accelerated filer** ☐ | **Accelerated filer** ☒ |
| **Non-accelerated filer** ☐ | **Smaller reporting company** ☐ |
| | **Emerging growth company** ☐ |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐ |

---

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (this "***Registration Statement***") is being filed with the Securities and Exchange Commission (the "***Commission")*** by Nutex Health Inc. (the "***Company***" or the "***Registrant***") for the purpose of registering 1,100,000 additional shares of the Company's common stock, par value of $0.001 per share (the "***Common Stock***"), for issuance under the Nutex Health Inc. Amended and Restated 2023 Equity Incentive Plan, as amended on July 14, 2025 (the "***2023 Plan***"). The increase in the number of shares authorized for issuance under the Plan was approved by our stockholders at our annual meeting held on July 14, 2025. The 1,100,000 shares of Common Stock being registered pursuant to this Registration Statement are in addition to the Company's Registration Statement on Form S-8 (File No. 333-267710) filed by the Registrant on September 30, 2022, and Registration Statement on Form S-8 (File No. 333-273402) filed by the Registrant on July 25, 2023 (the "***Prior Registration Statements***"), pursuant to which the Registrant previously registered an aggregate of 73,427 shares of Common Stock (as adjusted for the Reverse Split of 1 for 15 effected by the Company effective April 10, 2024 and the Reverse Split of 1 for 10 effected by the Company effective July 2, 2024) under the 2023 Plan. The additional shares of Common Stock being registered by this Registration Statement are of the same class as those securities registered on the Prior Registration Statements. In accordance with General Instruction E of Form S-8, the contents of the Prior Registration Statements, together with all exhibits filed therewith or incorporated therein by reference to the extent not otherwise amended or superseded by the contents hereof or otherwise, are incorporated herein by reference.

------

**PART II<br>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

---

| | |
|:---|:---|
| **Item 3.** | **Incorporation of Documents by Reference.** |

---

The following documents, filed by the Company with the Commission pursuant to the Securities Exchange Act of 1934, as amended, (the "Exchange Act") are incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• <u>[Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Commission on March 5, 2026 (the "Form 10-K")](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001479681/000162828026015168/nutx-20251231.htm)</u>; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The description of the Company's common stock, par value $.001 per share, contained in <u>[Exhibit 4.3](https://www.sec.gov/Archives/edgar/data/1479681/000162828026015168/ex43-descriptionofcapitals.htm)</u> to the Form 10-K.

In addition, all documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or portions thereof that are "furnished" and not "filed" in accordance with the rules of the Commission, shall not be deemed to be incorporated by reference in this Registration Statement.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4.&nbsp;&nbsp;&nbsp;&nbsp;Description of Securities.**

Not applicable.

**Item 5.&nbsp;&nbsp;&nbsp;&nbsp;Interests of Named Experts and Counsel.**

Not applicable.

**Item 6.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.**

Section 145(a) of the General Corporation Law of the State of Delaware, as amended ("DGCL") provides, in general, that a corporation may indemnify any person who was or is a party to or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

Section 145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper.

------

Section 145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section 145 of the DGCL. As permitted by the DGCL, the Registrant's amended and restated certificate of incorporation limits the liability of its directors to the fullest extent permitted by the DGCL providing that a director will not be personally liable for monetary damages to the Registrant or its stockholders for breach of fiduciary duty as a director to the extent so permitted. The amended and restated certificate of incorporation also provides that each current or former director, officer, employee or agent of the Registrant, or each such person who is or was serving or who had agreed to serve at the request of the Registrant as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or any other enterprise will be indemnified by the Registrant to the full extent permitted by law, as the same exists or may in the future be amended. The Registrant's bylaws provide that it will indemnify, and provide expense advancement to, its directors and officers to the fullest extent permitted by such law, subject to certain exceptions contained in the Registrant's amended and restated bylaws.

Pursuant to Section 102(b)(7) of the DGCL, the Registrant's Amended and Restated Certificate of Incorporation eliminates the liability of a director to the Registrant or its stockholders for monetary damages for breach of fiduciary duty as a director to the fullest extent permitted by the DGCL, as may be amended from time to time.

The Registrant has approved and entered into indemnification agreements with each of its directors and executive officers. These agreements provide that the Registrant will indemnify, and provide expense advancement and reimbursement to, each of its directors and such officers to the fullest extent permitted by law and its amended and restated certificate of incorporation and its bylaws, subject to certain exceptions contained in those agreements. Any claims for indemnification by the Registrant's directors and officers may reduce the Registrant's available funds to satisfy successful third-party claims against it and may reduce the amount of money available to the Registrant. The Registrant also maintains a general liability insurance policy, which will cover certain liabilities of directors and officers of the Registrant arising out of claims based on acts or omissions in their capacities as directors or officers.

**Item 7.&nbsp;&nbsp;&nbsp;&nbsp;Exemption from Registration Claimed.**

Not applicable.

------

---

| | |
|:---|:---|
| **Item 8.** | **Exhibits.** |

---

The following exhibits are filed as part of this Registration Statement:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | **Incorporation by Reference**<br>**(File No. 001-41346)** | **Incorporation by Reference**<br>**(File No. 001-41346)** | |
|<br>**Exhibit Number** |<br>**Description** | **Form** | **Exhibit** | **Filing**<br>**Date** |
| 3.1 | <u>[Second Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1479681/000155837023011705/nutx-20230629xex3d1.htm).</u> | 8-K | 3.1 | 7/5/2023 |
| 3.2 | <u>[Amendment to the Second Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1479681/000155837024004950/nutx-20240409xex3d1.htm).</u> | 8-K | 3.1 | 4/11/2024 |
| 3.3 | <u>[Amendment No. 2 to Second Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/1479681/000155335024000058/ex3x1.htm)</u> | 8-K | 3.1 | 7/5/2024 |
| 3.4 | <u>[Second Amended and Restated Bylaws](https://www.sec.gov/Archives/edgar/data/0001479681/000160706222000244/ex3_2.htm).</u> | 8-K | 3.2 | 4/4/2022 |
| 4.1 | <u>[Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan](https://www.sec.gov/Archives/edgar/data/1479681/000110465923062629/tm2313253d5_defa14a.htm)</u> | Schedule 14A | Appendix A | 5/19/2023 |
| 4.2 | <u>[Amendment No. 1 to the Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan](https://www.sec.gov/Archives/edgar/data/1479681/000162828026015168/ex47-amendmentno1totheamen.htm)</u> | 10-K | 4.7 | 3/5/2026 |
| 5.1\* | <u>[Opinion of Troutman Pepper Locke LLP](ex51.htm)</u> |  |  |  |
| 23.1\* | <u>Consent of Grant Thorton LLP, independent registered public accounting firm</u> |  |  |  |
| 23.3\* | <u>Consent of Marcum LLP, independent registered public accounting firm</u> |  |  |  |
| 23.2\* | <u>Consent of Troutman Pepper Locke LLP (contained in Exhibit 5.1)</u> |  |  |  |
| 107\* | <u>[Filing Fee Table](s-8filingfeetable.htm)</u> |  |  |  |

---

__________

\* Filed herewith

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, State of Texas, on the 9th day of March, 2026.

---

| | |
|:---|:---|
| **NUTEX HEALTH INC.** | **NUTEX HEALTH INC.** |
| By: | /s/ Thomas T. Vo |
|  | Thomas T. Vo, M.D.<br>*Chief Executive Officer* |

---

------

**SIGNATURES AND POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints each of Thomas T. Vo, M.D. and Jon C. Bates, acting alone or together with another attorney-in-fact, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.

---

| | |
|:---|:---|
| March 9, 2026 | /s/ Thomas T. Vo |
|  | Thomas T. Vo |
|  | Chief Executive Officer and Chairman of the Board<br>(principal executive officer) |
| March 9, 2026 | /s/ Jon C. Bates |
|  | Jon C. Bates |
|  | Chief Financial Officer<br>(principal financial officer and principal accounting officer) |
| March 9, 2026 | /s/ Warren Hosseinion |
|  | Warren Hosseinion |
|  | President and Director |
| March 9, 2026 | /s/ Kelvin Spears |
|  | Kelvin Spears |
|  | Director |
| March 9, 2026 | /s/ Cheryl Grenas |
|  | Cheryl Grenas |
|  | Director |
| March 9, 2026 | /s/ Michael L. Reed |
|  | Michael L. Reed |
|  | Director |
| March 9, 2026 | /s/ Frank E. Jaumot |
|  | Frank E. Jaumot |
|  | Director |
| March 9, 2026 | /s/ Scott J. Saunders |
|  | Scott J. Saunders |
|  | Director |

---

## Ex-Filing

**Exhibit 107**

**CALCULATION OF FILING FEE TABLE<br>FORM S-8**

(Form Type)

**NUTEX HEALTH INC.**<br> (Exact Name of Registrant as Specified in its Charter)

**Table 1: Newly Registered Securities**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered** <sup>(1)</sup> | **Proposed Maximum Offering Price Per Unit**<sup>(3)</sup> | **Maximum Aggregate Offering Price**<sup>(3)</sup> | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common Stock, $0.001 par value per share | Rule 457(c) and 457(h) | 1100000<sup>(2)</sup> | $90.24 | $99264000 | $138.10 per $1,000,000 | $13708.36 |
|  | <br>**Total Offering Amounts** | <br>**Total Offering Amounts** |  |  | $99264000 |  | $13708.36 |
|  | <br>**Total Fee Offsets** | <br>**Total Fee Offsets** |  |  | $— |  | $— |
|  | <br>**Net Fee Due** | <br>**Net Fee Due** |  |  |  |  | $13708.36 |

---

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement on Form S-8 also covers any additional number of shares of common stock, par value $0.001 per share ("Common Stock") that become issuable under the Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan, as amended (the "2023 Plan"), by reason of any stock splits, stock dividends or other distribution, recapitalization or similar transaction effected without receipt of consideration.

(2) Consists of an additional 1,100,000 shares of Common Stock of Nutex Health Inc., authorized for issuance under the Nutex Health Inc. Amended and Restated 2023 Equity Incentive Plan, as amended on July 14, 2025, as approved by the Company's stockholders at its annual meeting held on July 14, 2025.

(3) Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(h)(1) and Rule 457(c) under the Securities Act, and based on the average of the high and low sales price per share of the registrant's Common Stock on the Nasdaq Stock Market LLC on March 2, 2026

## Exhibit 5.1

Troutman Pepper Locke LLP600 Travis St., Suite 2800<br>Houston, TX 77002<br>troutman.com

![image_0.jpg](image_0.jpg)

March 9, 2026

Nutex Health Inc.

1776 Yorktown St, Suite 700

Houston, Texas 77056

---

| | |
|:---|:---|
| Re: | Registration Statement on Form S-8<br>1,100,000 shares of Nutex Health Inc. Common Stock, $0.001 par value per share |

---

Ladies and Gentlemen:

We have acted as special counsel to Nutex Health Inc., a Delaware corporation (the "***Company***"), in connection with the proposed issuance by the Company of an aggregate of up to 1,100,000 shares of common stock of the Company, $0.001 par value per share ("***Common Stock***"), which are additional shares (the "***Shares***") of Common Stock approved by the Company's stockholders on July 14, 2025, for issuance pursuant to the Amended and Restated Nutex Health Inc. 2023 Equity Incentive Plan, as amended on July 14, 2025 (the "***2023 Plan***"). The Shares are included in a registration statement on Form S-8 under the Securities Act of 1933, as amended (the "Act"), filed with the Securities and Exchange Commission (the "***Commission***") on the date hereof (the "***Registration Statement***"). This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related prospectus, other than as expressly stated herein with respect to the issuance of the Shares.

As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied, without verification, upon certificates of public officials and upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware and we express no opinion with respect to any other laws.

Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, when the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated by the 2023 Plan assuming that the individual grants or awards under the 2023 Plan are duly authorized by all necessary corporate action and duly granted or awarded and exercised in accordance with the requirements of law and the 2023 Plan (and the agreements and awards duly adopted thereunder and in accordance therewith), the issuance and sale of the Shares will have been duly authorized by all necessary corporate action of the Company, and the Shares will be validly issued, fully paid and non-assessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of Delaware.

This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder.

---

| |
|:---|
| Sincerely, |
| /s/ Troutman Pepper Locke LLP |

---

<br>